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the group of 416 allografted patients, the cumulative prob-
ability of SMN being 6.8 at 10 years. Since the number of
expected cases in the general population is 0.62, the ratio of
observed to expected cases is 3.2 (p < 0.001). This ﬁgure
means that the risk of developing a malignant neoplasm in
allografted individuals using our method is 3.2 times higher
than that in the general population. There were three non-
Hodgkin’s lymphomas (NHL), two M2 acute myelogenous
leukemias (AML), one hairy cell leukemia, one tongue
epidermoid carcinoma and one breast carcinoma. In
conclusion, we have found a low incidence of SMN in this
group of Mexican patients allografted with the Mexican
reduced-intensity conditioning method. Possible explana-
tions for this difference are discussed, focusing on the RIC
preparative regimen.387
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Objective: To demonstrate the efﬁcacy and safety of a
reduced intensity conditioning (RIC) regimen comprising
Fludarabine and intravenous Busulfan (FB2) in patients un-
dergoing allogeneic peripheral blood stem cell trans-
plantation (PBSCT) for hematological disorders.
Patients and Methods: We conducted a retrospective anal-
ysis of 42 patients who underwent RIC prior to PBSCT at our
institution between the years 2009 and 2012 inclusive. FB2
consisted of Fludarabine 30 mg/m2/day infused over 30 mi-
nutes for 5 days on days -6 through -2 and Busulfan 3.2 mg/
kg/day on days -3 and -2 (infusion rate 80 mg/kg/hour). All
patients received Thymoglobulin at a total dose of 4.5 mg/kg
or 6 mg/kg administered in divided doses on days -2, -1 and
0. Post-transplantation graft versus host disease (GVHD)
prophylaxis consisted of tacrolimus and mycophenolate
mofetil. Diagnoses included Acute Myeloid Leukemia (n¼3),
Acute Lymphoblastic Leukemia (n¼2), Myelodysplastic Syn-
drome (n¼10), Severe Aplastic Anemia (n¼5), Chronic Lym-
phocytic Lymphoma (n¼8), Non-Hodgkin’s Lymphoma
(n¼8), Hodgkin Lymphoma (n¼4) and Myeloproliferative
Disorder (n¼2). The median age of the recipients was 56
years with 18 patients (44%) aged> 60 years. Only 9 patients
(21%) were in complete remission (CR) at the time of HSCT
and 19 (45%) were considered to have high-risk disease by
CIBMTR criteria. The co-morbidity index was 3 or more in 19
recipients (45%).
Results: At a median follow up of 15 months, overall survival
(OS) for the entire cohort was 62%. OS for patients under-
going PBSCT in CR versus not in CR was 89% and 55%
respectively. OS was similar in recipients undergoing PBSCT
from matched unrelated (n¼29) or matched related (n¼13)
donors. Median engraftment time for neutrophils (ANC>500) and platelets (>20K) was 18 and 17 days, respectively.
Acute GVHD grade 2 developed in 15 (36%) of recipients,
grade 3 in 2 (5%) and grade 4 in 2 (5%). The cumulative
incidence of relapse was 37% (n¼13). There were no graft
failures and treatment relatedmortality (TRM)was 2% (n¼1).
At one year following PBSCT, 10 patients (24%) had extensive
chronic GVHD and 19 patients (45%) required continuation of
immunosuppressants. All patients with SAA (n¼5) are alive,
engrafted and did not develop grade 3 or 4 acute GVHD.
Conclusion: Our preliminary data demonstrates low toxicity
and favorable outcome in older patients with elevated co-
morbidity score and high-risk disease using the FB2 regimen.
The efﬁcacy, tolerability and excellent outcome of FB2 war-
rants further study in recipients with SAA.388
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Introduction: Graft Versus Host Disease (GVHD) and
immunosuppression in allogeneic hematopoietic stem cell
transplant (alloHSCT) patients can contribute to cytomega-
lovirus (CMV) disease. CMV disease of the gut is associated
with intestinal necrosis and ulceration and can lead to
debilitating diarrhea. Diagnostic evaluation includes assess-
ment for CMV viremia and intestinal biopsy to conﬁrm
diagnosis. Adequate research supporting intestinal biopsy in
serum negative patients does not exist. In an effort to
potentially minimize use of invasive endoscopic procedures
to rule out CMV as a cause for diarrhea, we evaluated the
diagnostic yield of intestinal biopsies in the work-up of
allograft recipients presenting with diarrhea.
Methods: This retrospective study evaluated a total of 485
patients that underwent alloHSCT after 2006 and were
admitted to the inpatient BMT service between January 1st,
2008 and April 30th, 2013. A subset of patients was identiﬁed
that completed esophagogastroduodenoscopy (EGD) or co-
lonoscopy for work-up of diarrhea. Comparisons were made
between serum CMV PCR (108 bp primer directed at CMV
Immediate Early antigen product) and gastrointestinal bi-
opsy (with morphologic evaluation for cytopathic effect and
immunohistochemistry for immediate early non-structural
antigen). Pathologic evaluation conﬁrmed gut-associated
CMV disease.
Results: CMV viremia was evident the day of intestinal bi-
opsy 25% (99 total biopsies) of the time. Nine biopsies (9%) in
7 different patients were positive for CMV and conﬁrmed
CMV gut disease. Of these, 6 patients had corresponding
CMV viremia. One patient (cord blood recipient) was diag-
nosed with CMV gut disease by biopsy alone. Signiﬁcant
association (p¼0.003) and agreement (p¼0.006) between
CMV viremia and CMV gut disease were observed in this
cohort, although we do note discordances of interest. No
apparent association between lymphocyte count and the
presence of CMV intestinal diseasewas observed (p¼0.23). In
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100% of patients with CMV viremia and no CMV gut disease
were lymphopenic. There did not appear to be any associa-
tion between CMV PCR copy number and absolute lympho-
cyte count (r¼0.016; p¼0.49). There was no apparent pattern
or relationship between CMV PCR copy number and degree
of cytopathic changes on intestinal biopsy.
Conclusion: We hypothesized that all patients with gut-
associated CMV disease would have corresponding CMV
viremia. One patient with biopsy-proven disease had nega-
tive CMV PCR, so we are evaluating for potential sources of
false positivity because gut-conﬁned CMV (CMV disease
without CMV viremia) is relatively uncommon in the HSCT
setting. Our data support that a lack of CMV viremia does not
rule out gut-associated CMV disease and that intestinal bi-
opsy by EGD or colonoscopy is warranted in this patient
population.389
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Patients with end stage renal disease (ESRD) historically have
not been offered allogeneic hematopoietic cell trans-
plantation (HCT) because of the presumed high risk of
toxicity. Use of nonmyeloablative (NMA) conditioning regi-
mens has made allogeneic HCT a viable option for patients
with variety of baseline medical comorbidities. We report
our experience with NMA allogeneic HCT for patients with
ESRD who were on hemodialysis (HD) or peritoneal (PD)
before receiving NMA allogeneic HCT. We reviewed our
institutional database at Fred Hutchinson Cancer Research
Center from 1997-2013. Eight patients were on dialysis (7 on
HD and 1 on PD) before they received NMA allogeneic HCT
(Age: 13-67; F/M: 3/5). Six of eight patients (75%) were on
dialysis when the decision for NMA allogeneic HCT was
made. One patient was started on HD before the conditioning
regimen and one required HD after ﬁnishing the condition-
ing and before the infusion of stem cells. Etiologies of ESRD
included: Myeloma kidney (3), polycystic kidney disease (2),
hemolytic uremic syndrome secondary to E-coli infection (1),
acute tubular necrosis (ATN) (1) and acute obstructive kidney
injury (AKI) (1). Four patients (50%) had previously received
an autologous transplant (as part of an auto/allo tandem
approach). Primary diagnosis included multiple myeloma
(n¼4), NHL (n¼2) MDS/MPN (n¼1), WiskotteAldrichTable
Results of treosulfan use in conditioning in children vs adults
Children
Toxicity Diarrhea (24%), stomatitis (22%), SGOT (25%
aGVHD III-IV 10%
Limited cGVHD 13%
Extended cGVHD 6%
3y OS ALL-51%, AML-46%,
inherited disorders-80%, hemoglobinopath
Other 3y EFS ALL-39% AML-40%syndrome (n¼1). The conditioning regimen included Flu-
darabine/2GyTBI (n¼3), 2GyTBI (n¼1), Fludarabine/
Melphalan/2GyTBI (n¼1) and Fludarabine/Cyclophospha-
mide/2GyTBI (n¼1). Fludarabine and Melphalan were
administered after dialysis but with no dose reduction.
Immunosuppression included Mycophenolate mofetil with
cyclosporine (n¼5) or Tacrolimus (n¼3). Seven of eight pa-
tients died during the follow-up period (median 10.1; range
0.2-84.6 months). Two patients died within 2 weeks after
transplant and neither was on dialysis at the time of referral
for HCT. One had progressive Mantle cell lymphoma and was
started on HD 7 days before the HCT because of obstructive
AKI secondary to abdominal lymphadenopathy and the
second patient had a diagnosis of multiple myeloma and
required HD because of ATN after the conditioning regimen
before stem cell infusion. This patient died from multi-sys-
tem organ failure secondary to conditioning regimen-related
toxicities (Flu/Mel/TBI). All other 7 patients survived for a
median of 11.5 months (range 3.8 e 84.6). Causes of death
included: CMV pneumonia, fungal CNS infection, uncon-
trolled bleeding during open heart surgery, relapse, and
sepsis. One patient is still alive 3.8 months post auto/allo
HCT. In conclusion, review of these cases indicates that NMA
allogeneic SCT for patients with ESRD on dialysis at the time
of referral did not lead to adverse outcomes but initiation of
dialysis shortly before HCT was associated with early mor-
tality after transplant.390
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Objective: The published literature was reviewed to assess
the impact of treosulfan for conditioning before allogeneic or
autologous SCT to identify possible differences between
children and adults with respect to toxicity, acute or chronic
graft versus host disease (a/cGVHD), treatment related
mortality (TRM), overall survival (OS), disease free survival
(DFS).
Material and Methods: Pediatric (patients aged <18 years)
data originated from EBMT megaﬁle report (EBMT Annual
Meeting 2012) and 1 study of 28 patients from India. Adult
data originated from 34 studies from European countries
(Germany, Poland, Italy, France, Finland, Italy), Israel (4
studies, 119 patients) and USA (1 study, 60 patients). The
analysis was performed based on data published before
October, 1st, 2013. Pediatric data included 604 (521 allo + 83
auto) evaluable patients out of total 871 patients reported.Adults
) Gastro-intestinal II (up to 33%), III-IV (10-29%)
Median 23% (range 14-50)
Median 42% (range 16-72)
14-16%
ies-93%
Median 61% (range 36-85)
Median 2y DFS 55% (range 35-82),
RI 25% (range 15-36), 100d TRM 11.8%.
